Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-25T10:28:15.478Z Has data issue: false hasContentIssue false

Chapter 4 - Monoamine oxidase inhibitors in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
Sven-Eric Pålhagen
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 23 - 33
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Löhle, M, Reichmann, H. Clinical neuroprotection in Parkinson's disease – still waiting for the breakthrough. J Neurol Sci 2010; 289: 104–14.CrossRefGoogle ScholarPubMed
Löhle, M, Reichmann, H. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol 2011; 11: 112.Google Scholar
Fabbrini, G, Abbruzzese, G, Marconi, S, Zappia, M. Selegiline: a reappraisal of its role in Parkinson disease. Clinical Neuropharmacol 2012; 35: 134–40.Google Scholar
Goetz, CG, Koller, WC, Poewe, W. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17 (Suppl. 4): S1–166.Google Scholar
Goetz, CG, Poewe, W, Rascol, O, Sampaio, C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523–39.Google Scholar
Macleod, A, Counsell, C, Ives, N, Stowe, R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005; 20: CD004898.Google Scholar
National Collaborating Centre for Chronic Conditions. Parkinson’s Disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Guidelines for the NHS by NICE. London: Royal College of Physicians, 2006.Google Scholar
Pahwa, R, Factor, SA, Lyons, KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983–95.Google Scholar
Ryton, BA, Liddle, BJ. Implementing NICE clinical guidelines on Parkinson's disease Clin Med 2009; 9: 436–40.Google Scholar
Caslake, R, Macleod, A, Ives, N, Stowe, R, Counsell, C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev 2009; (4): CD006661.Google Scholar
Brainin, M, Barnes, M, Baron, JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol 2004, 11: 577–81.Google Scholar
Horstinka, ME, Tolosa, E, Bonuccelli, U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170–85.Google Scholar
Horstinka, ME, Tolosa, E, Bonuccelli, U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part II: late(complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186–202.Google Scholar
Leone, MA, Brainin, M, Boon, P, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012. Eur J Neurol 2013; 20: 410–19.Google Scholar
Fox, S, Katzenschlager, R, Lim, SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Dis 2011; 26 (Suppl. 3): S2–41.Google Scholar
Ferreira, JJ, Katzenschlager, R, Bloem, BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5–15.CrossRefGoogle ScholarPubMed
Knoll, J, Vizi, ES, Somogyi, E. Phenylisopropyl-methylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effect of tyramine. Drug Res 1968; 18: 109–12.Google Scholar
Szende, B, Bokonyi, G, Bocsi, J, et al. Anti-apoptotic and apoptotic action of (–)-deprenyl and its metabolites. J Neural Transm 2001; 108: 25–33.Google Scholar
Matsubara, K, Senda, T, Uezono, T, et al. l-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and β-carbolinium: a microdialysis study in rats. Neurosci Lett 2001; 302: 65–8.Google Scholar
Tatton, W, Chalmers-Redman, R, Tatton, N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003; 110: 509–15.Google Scholar
Magyar, K, Szende, B. (–)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004; 25: 233–42.Google Scholar
Saravanan, KS, Sindhu, KM, Senthilkumar, KS, Mohanakumar, KP. l-Deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 2006; 49: 28–40.CrossRefGoogle ScholarPubMed
Birkmayer, W, Knoll, J, Riederer, P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985; 64: 113–27.Google Scholar
Blume, E. Street drugs yield primate Parkinson's model. JAMA 1983; 250: 13–14.Google Scholar
Langston, JW, Ballard, PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983; 309: 310.Google Scholar
Tetrud, JW, Langston, JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519–22.Google Scholar
Myllylä, VV, Sotaniemi, KA, Aasly, J, et al. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol 1993; 60: 676–80.Google Scholar
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression and disability in early Parkinson's disease. N Engl J Med 1993; 328: 176–83.Google Scholar
Shoulson, I, Oakes, D, Fahn, S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604–12.Google Scholar
Olanow, CW, Hauser, RA, Gauger, L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease Ann Neurol 1995; 38: 771–77.Google Scholar
Pålhagen, S, Heinonen, EH, Hägglund, J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520–5.CrossRefGoogle ScholarPubMed
Pålhagen, S, Heinonen, EH, Hägglund, J, et al. Selegiline delays the onset of disability in de novo Parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520–5.Google Scholar
Pålhagen, SE, Heinonen, E. Use of selegiline as monotherapy and in combination with levodopa in the management of Parkinson's disease: perspectives from the MONOCOMB Study. Prog Neurother Neuropsychopharmacol 2008; 3: 49–71.Google Scholar
Ives, NJ, Stowe, RL, Marro, J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329: 593.Google Scholar
Parkinson Study Group. A randomized placebo controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241–8.Google Scholar
Rascol, O, Brooks, DJ, Melamed, E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005; 365: 947–54.Google Scholar
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937–43.Google Scholar
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561–6.Google Scholar
Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.Google Scholar
Schapira, A, Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 2011; 25: 1061–71.CrossRefGoogle ScholarPubMed
Ondo, WG, Sethi, KD, Kricorian, G. Selegilime orally disintegrating tablets in patient with Parkinson's disease and “wearing off” symptoms. Clin Neuropharmacol 2007; 30: 295–300.CrossRefGoogle ScholarPubMed
Montastruc, JL, Chaumerliac, C, Desboeuf, K, et al. Adverse drug reactions to selegiline: a review of the French pharmaco vigilance database. Clin Neuropharmacol 2000; 23: 271–5.CrossRefGoogle Scholar
Lees, AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of UK. BMJ 1995; 311: 1602–7.Google Scholar
Thorogood, M, Armstrong, B, Nichols, T, Hollowell, J. Mortality in people taking selegiline; observational study. BMJ 1998; 327: 252–4.Google Scholar
Reichmann, H, Jost, WH. Efficacy and tolerability of rasagiline in daily clinical use – a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol 2010; 17: 1164–71.Google Scholar
Jost, W, Friede, M, Schnitker, J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease. Basal Ganglia 2012; 2: S17–26.Google Scholar
Richard, IH, Kurland, R, Tanner, C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997; 48: 1070–7.CrossRefGoogle Scholar
Connolly, BS, Fox, SH. Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Rev Neurother 2012; 12: 1439–49.Google Scholar
Connolly, BS, Lang, AE. Pharmacological treatment of Parkinson disease. A review. JAMA 2014; 311: 1670–83.Google Scholar
Naoi, M, Maruyama, W, Inaba-Hasegawa, K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 2013; 13: 671–84.Google Scholar
Youdim, MB. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp Neurobiol 2013; 22: 1–10.Google Scholar
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364–71.Google Scholar
Myllylä, VV, Sotaniemi, KA, Vuorinen, JA, Heinonen, EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339–43.Google Scholar
Przuntek, H, Kuhn, W. The effect of R-(–)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm Suppl 1987; 25: 97–104.Google Scholar
Sivertsen, B, Dupont, E, Mikkelsen, B, et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand Suppl 1989; 126: 147–52.Google Scholar
Nappi, G, Martignoni, E, Horowski, R, et al. Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurol Scand 1991; 83: 407–10.Google Scholar
Lees, AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602–7.Google Scholar
Larsen, JP, Boas, J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian–Danish 5-year study. Norwegian–Danish Study Group. Mov Disord 1997; 12: 175–82.Google Scholar
Larsen, JP, Boas, J, Erdal, JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian–Danish Study Group. Eur J Neurol 1999; 6: 539–47.CrossRefGoogle Scholar
Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469–72.Google Scholar
Heinonen, EH, Myllylä, V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998; 19: 11–22.CrossRefGoogle ScholarPubMed
Lieberman, AN, Gopinathan, G, Neophytides, A, Foo, SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. NY State J Med 1987; 87: 646–9.Google Scholar
Golbe, LI, Lieberman, AN, Muenter, MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45–55.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×